Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Type 2 Diabetes Mellitus (T2DM), Coronar...
Phase PHASE4
Enrollment 144
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, randomized controlled trial to test whether an SGLT2 inhibitor (dapagliflozin), a type of diabetes medication, can slow down or even reverse the progression of coronary atherosclerosis (plaque buildup in the coronary arteries) in patients with type 2 diabetes. The effect may be mediated by improving the function of perivascular adipose tissue. A total of 144 adults with type 2 diabetes and stable coronary artery disease will be randomly assigned to receive either dapagliflozin plus standard diabetes and cardiovascular care (intervention group) or standard care alone (control group) for 18 months. Serial coronary CT angiography and other assessments will be performed to evaluate changes in coronary plaque volume, CT-derived fractional flow reserve, perivascular fat radiomics score, and various metabolic and inflammatory markers, to determine whether SGLT2 inhibition reduces cardiovascular risk.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Dapagliflozin (DAPA) — Dapagliflozin 10 mg tablet administered orally once daily for 18 months, in addition to standard diabetes and cardiovascular care, to evaluate its effects on coronary atherosclerosis progression mediated by perivascular adipose tissue in patients with type 2 diabetes.
  • Other: Standard Care (Treatment as Usual) — Standard glycemic and cardiovascular management according to clinical guidelines, excluding SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors, for 18 months.

Primary Outcomes

  • Progression of Coronary Plaque Volume and Proportion from Baseline to the 18-Month Follow-Up (Baseline to 18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-01-01
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 144 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Junjie Yang
Contact Information
Study Contact:
Junjie Yang, MD
010-55499209
fearlessyang@126.com
Junjie Yang
010-55499345
fearlessyang@126.com
The First Medical Center of Chinese PLA General Hospital
Junjie Yang, MD
010-55499209
fearlessyang@126.com
The Sixth Medical Center of Chinese PLA General Hospital
Interventions
  • Drug: Dapagliflozin (DAPA) — Dapagliflozin 10 mg tablet administered orally once daily for 18 months, in addition to standard diabetes and cardiovascular care, to evaluate its effects on coronary atherosclerosis progression mediated by perivascular adipose tissue in patients with type 2 diabetes.
  • Other: Standard Care (Treatment as Usual) — Standard glycemic and cardiovascular management according to clinical guidelines, excluding SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors, for 18 months.
Study Locations (2 sites)
The First Medical Center of Chinese PLA General Hospital, Beijing, Beijing Municipality China
The Sixth Medical Center of Chinese PLA General Hospital, Beijing, Beijing Municipality China
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 75 years. * Confirmed diagnosis of type 2 diabetes mellitus with SCORE2-Diabetes risk score \>10%. * Stable angina pectoris. * Coronary CT angiography (CCTA) demonstrating 50%-90% stenosis in at least one coronary vessel with diameter ≥2.5 mm. * CT-derived fractional flow reserve (CT-FFR) \>0.8 in the target vessel. * Stable standard therapy for diabetes and cardiovascular disease, with no changes in SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors within the past 4 weeks. * Able and willing to provide written informed consent. Exclusion Criteria: * History of coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI) with stenting, prosthetic valve replacement, or permanent pacemaker implantation. * New York Heart Association (NYHA) functional class III or IV heart failure. Acute myocardial infarction within the previous 30 days. * Known allergy to iodinated contrast media or other contraindications to CCTA. Severe arrhythmia or coronary artery calcium (CAC) score \>400. * Estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73 m². History of serious adverse reactions to SGLT2 inhibitors. * Pregnancy, lactation, or planned pregnancy during the study period. Severe liver dysfunction (Child-Pugh class C). * Any other condition that, in the investigator's opinion, makes the participant unsuitable for the trial.
Conditions Systemic Arterial Hypertension, Inflamma...
Phase NA
Enrollment 48
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to evaluate the effect of the royal jelly and propolis on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Placebo — The placebo group will receive 4 capsules per day (containing microcrystalline cellulose and magnesium stearate in colored gelatin capsules capable of masking the appearance of the internal content), at the same time for 2 months.
  • Dietary Supplement: Royal Jelly + Propolis Group — Participants will receive 4 capsules per day, providing the dosage of 300mg of royal jelly + 500mg propolis for 2 months (8 weeks).

Primary Outcomes

  • Change of inflammatory citokynes (Baseline and 2 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-15
Completion: 2027-12-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universidade Federal Fluminense
Principal Investigators:
  • Ludmila Cardozo, PhD (STUDY_DIRECTOR) - Universidade Federal Fluminense
Contact Information
Study Contact:
Denise Mafra, PhD
+5521985683003
dmafra30@gmail.com
Ludmila cardozo
+55987333185
ludmilacardozo@id.uff.br
Denise Mafra
Interventions
  • Dietary Supplement: Placebo — The placebo group will receive 4 capsules per day (containing microcrystalline cellulose and magnesium stearate in colored gelatin capsules capable of masking the appearance of the internal content), at the same time for 2 months.
  • Dietary Supplement: Royal Jelly + Propolis Group — Participants will receive 4 capsules per day, providing the dosage of 300mg of royal jelly + 500mg propolis for 2 months (8 weeks).
Study Locations (1 sites)
Denise Mafra, Niterói, Rio de Janeiro 24220-900 Brazil
Eligibility Criteria
Inclusion Criteria: * Diagnosis of stage 1 and 2 hypertension * Regular treatment for more than 6 months * There have been no changes in medication doses over the last three months. Exclusion Criteria: * Autoimmune and infectious diseases, diabetes * Chronic kidney disease, liver disease, cancer and AIDS * Pregnant women * Use of catabolic drugs or antibiotics * Use of antioxidant vitamin supplements, prebiotics, probiotics, symbiotic * Habitual intake of royal jelly and propolis
Conditions Chemotherapy-Related Taste Alteration
Phase NA
Enrollment 68
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Taste alteration is a common and distressing symptom experienced by women with breast cancer receiving taxane-based chemotherapy. This symptom may negatively affect food intake, nutritional status, psychological well-being, and quality of life. Although several approaches have been suggested for the management of chemotherapy-related taste alteration, evidence regarding structured nurse-led self-management interventions in this patient group remains limited.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Nurse-led Self-Management Program — This 8-week nurse-led self-management program is a behavioral supportive care intervention designed specifically for women with breast cancer receiving taxane-based chemotherapy. The program focuses on the self-management of taxane-related taste alteration and associated nutritional problems. It includes structured nurse-led education, regular assessment of taste-related symptoms, self-monitoring of taste changes and food-related difficulties, individualized counseling, goal setting, problem-solving support, and practical strategies to maintain food intake and quality of life during chemotherapy. The intervention is delivered in addition to routine care and differs from general chemotherapy education by specifically integrating taste alteration management, nutritional self-management, and nurse-led follow-up within a structured 8-week program.

Primary Outcomes

  • Change in Chemotherapy-Induced Taste Alteration Scale Score (Baseline, Week 5, and Week 9)
  • Change in Nutritional Risk Score (Baseline, Week 5, and Week 9)
  • Change in Quality of Life Score (Baseline, Week 5, and Week 9)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-16
Completion: 2026-08-24
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 68 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Izmir Bakircay University
Contact Information
Study Contact:
Pinar Zorba Bahceli, PhD
+90 553 487 25 50
pinarzorba85@gmail.com
Esra Ozel, RN
+90 543 227 98 13
esra.kocakaplan.1905@gmail.com
Pinar Zorba Bahceli, PhD
+90 553 487 25 50
pinarzorba85@gmail.com
Izmir Provincal Health Directorate Izmir City Hospital
Interventions
  • Behavioral: Nurse-led Self-Management Program — This 8-week nurse-led self-management program is a behavioral supportive care intervention designed specifically for women with breast cancer receiving taxane-based chemotherapy. The program focuses on the self-management of taxane-related taste alteration and associated nutritional problems. It includes structured nurse-led education, regular assessment of taste-related symptoms, self-monitoring of taste changes and food-related difficulties, individualized counseling, goal setting, problem-solving support, and practical strategies to maintain food intake and quality of life during chemotherapy. The intervention is delivered in addition to routine care and differs from general chemotherapy education by specifically integrating taste alteration management, nutritional self-management, and nurse-led follow-up within a structured 8-week program.
Study Locations (1 sites)
Izmir Provincal Health Directorate Izmir City Hospital, Izmir, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or older * Literate * Diagnosed with breast cancer * Receiving taxane-based chemotherapy * Having a score of 1 or 2 for taste alteration according to the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) after the first cycle of chemotherapy * Willing to participate in the study and providing written informed consent Exclusion Criteria: * Having any communication barrier that prevents participation in the study * Having a diagnosed psychiatric disorder * Receiving radiotherapy * Having metastasis * Having a diagnosed physical disease that may affect food intake, such as ulcerative colitis or Crohn's disease * Receiving enteral or parenteral nutrition support
Conditions Late-Life Depression, Anhedonia
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This project focuses on clinical translational research into personalized transcranial alternating current stimulation (tACS) for treating anhedonia in late-life depression (LLD). Key components include: (1) Optimizing individualized tACS treatment parameters through randomized, double-blind, controlled trials and establishing precise treatment protocols using deep learning algorithms; (2) Assessing the short-term (2 weeks) and long-term (3 months) efficacy of tACS on depressive symptoms and anhedonia using scales such as the HAMD, SHAPS, and DARS, while monitoring safety; (3) Integrating multimodal detection technologies (64-channel EEG, inflammatory factors/neurotransmitters, etc.) to elucidate the mechanisms by which tACS alleviates anhedonia through modulating prefrontal neural oscillations (y-band), improving synaptic plasticity (increased BDNF), and regulating neurotransmitters (5-HT, DA). This study will establish, for the first time, an individualized parameter system for tACS treatment of LLD, providing a novel non-pharmacological intervention strategy for clinical practice.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: Transcranial Alternating Current Stimulation (tACS) — divided into a real-stimulus group and a sham-stimulus group
  • Device: shame tACS — The sham tACS group received 40 Hz tACS with a peak-to-peak amplitude of 1 mA, a frequency of y, and a sinusoidal waveform. The stimulation sites were located in the prefrontal cortex (F3 and F4) based on the 10-20 system of international EEG electrode placement, with CZ serving as the return electrode, which did not generate stimulation pulses.

Primary Outcomes

  • Dimensional Anhedonia Rating Scale (DARS) (12 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-16
Completion: 2027-12-31
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jie Li
Contact Information
Study Contact:
Daliang Sun Da liang Sun, Doctor
+86 88188876
474929588@qq.com
Daliang Sun, Doctor
+86 88188876
474929588@qq.com
Tianjin Anding Hospital
Interventions
  • Device: Transcranial Alternating Current Stimulation (tACS) — divided into a real-stimulus group and a sham-stimulus group
  • Device: shame tACS — The sham tACS group received 40 Hz tACS with a peak-to-peak amplitude of 1 mA, a frequency of y, and a sinusoidal waveform. The stimulation sites were located in the prefrontal cortex (F3 and F4) based on the 10-20 system of international EEG electrode placement, with CZ serving as the return electrode, which did not generate stimulation pulses.
Study Locations (1 sites)
Tianjin Anding Hospital, Tianjin, Tianjin Municipality 300222 China
Eligibility Criteria
Inclusion Criteria: * (1) Patients were interviewed using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) - Clinical Version (SCID-5-CV) to confirm that they met the DSM-5 diagnostic criteria for "major depressive disorder"; (2) Age ≥ 60 years; gender not restricted; (3) Hamilton Depression Scale (HAMD)-17 score \> 24 Exclusion Criteria: \- (1) History of severe head trauma or serious neurological conditions such as epilepsy; (2) Any brain devices or implants, including cochlear implants and aneurysm clips; treatments such as transcranial direct current stimulation (tDCS). (3) Individuals who have undergone other physical modulation therapies within the past 8 weeks, including but not limited to non-convulsive electroconvulsive therapy, repetitive transcranial magnetic stimulation, and transcranial direct current stimulation.
Conditions Breast Cancer, Breast Lymphedema
Phase NA
Enrollment 99
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer patients often develop breast lymphedema after breast-conserving surgery and radiotherapy, causing swelling, pain, and heaviness that affect quality of life. This study compares two physical therapy approaches-Kinesio Taping and compression therapy-for relieving breast lymphedema. Kinesio Taping is an elastic medical tape applied to the breast skin to promote lymphatic drainage; compression therapy uses an adjustable pressure vest to reduce swelling through external pressure. The study will enroll 99 eligible postoperative breast cancer patients, randomly assigned to three groups: one receiving routine care, one receiving routine care plus Kinesio Taping, and one receiving routine care plus compression therapy, with a 6-week intervention period. Assessments will be conducted at baseline, immediately after intervention, and at 3 and 6 months post-intervention to compare changes in swelling, pain, and quality of life among the three groups. This study has been approved by the Medical Ethics Committee of Tangshan People's Hospital (LLKS), and all participants voluntarily participate with signed informed consent.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Routine Care — Health education including explanation of breast lymphedema mechanisms and complications; breast and skin care instructions (cleaning with warm water and mild cleanser, avoiding irritants, wearing loose clothing, avoiding sun exposure for 6 months after radiotherapy); lifestyle guidance (high-protein, high-vitamin, low-fat diet, adequate sleep, proper positioning to promote lymphatic drainage); and rehabilitation exercises (range of motion exercises for the affected upper extremity, performed 1-2 times daily, 10-20 minutes per session, over a 6-week period).
  • Other: Kinesio Taping — Elastic therapeutic tape (KT TAPE, 25 cm × 5 cm pre-cut) applied to the affected breast. Prior to application, a 2 cm × 2 cm test tape is applied to the forearm for 24 hours to rule out allergy. The tape is cut into a fan shape with 4 tails, anchored below the clavicle, and applied diagonally around the breast area with no tension on the tails, covering the edematous area without overlapping. Each application is retained for 3 days, followed by 1 day of rest, repeated over a 6-week period. Participants are instructed on proper removal techniques (skin-pressing and rolling methods) to avoid skin damage.
  • Other: Compression Therapy — Adjustable compression vest made of medical-grade material with a modal inner layer, featuring adjustable Velcro straps on the affected side. Pressure is calibrated using a German precision pressure measurement device, with the sensor placed on the lower outer quadrant of the affected breast to maintain pressure at 18-21 mmHg. The vest is worn for 15-18 hours per day (daytime only, not at night) for 6 weeks. Participants are instructed to discontinue use immediately if they experience dyspnea or chest tightness.

Primary Outcomes

  • Lymphedema-Related Symptoms (VAS) (Baseline (T0), immediately post-intervention at 6 weeks (T1), 3 months post-intervention (T2), and 6 months post-intervention (T3))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2027-05-26
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 99 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tangshan People's Hospital
Contact Information
Study Contact:
shuo wang
+86 18168499773
2624592433@qq.com
Tangshan People's Hospital
Interventions
  • Other: Routine Care — Health education including explanation of breast lymphedema mechanisms and complications; breast and skin care instructions (cleaning with warm water and mild cleanser, avoiding irritants, wearing loose clothing, avoiding sun exposure for 6 months after radiotherapy); lifestyle guidance (high-protein, high-vitamin, low-fat diet, adequate sleep, proper positioning to promote lymphatic drainage); and rehabilitation exercises (range of motion exercises for the affected upper extremity, performed 1-2 times daily, 10-20 minutes per session, over a 6-week period).
  • Other: Kinesio Taping — Elastic therapeutic tape (KT TAPE, 25 cm × 5 cm pre-cut) applied to the affected breast. Prior to application, a 2 cm × 2 cm test tape is applied to the forearm for 24 hours to rule out allergy. The tape is cut into a fan shape with 4 tails, anchored below the clavicle, and applied diagonally around the breast area with no tension on the tails, covering the edematous area without overlapping. Each application is retained for 3 days, followed by 1 day of rest, repeated over a 6-week period. Participants are instructed on proper removal techniques (skin-pressing and rolling methods) to avoid skin damage.
  • Other: Compression Therapy — Adjustable compression vest made of medical-grade material with a modal inner layer, featuring adjustable Velcro straps on the affected side. Pressure is calibrated using a German precision pressure measurement device, with the sensor placed on the lower outer quadrant of the affected breast to maintain pressure at 18-21 mmHg. The vest is worn for 15-18 hours per day (daytime only, not at night) for 6 weeks. Participants are instructed to discontinue use immediately if they experience dyspnea or chest tightness.
Study Locations (1 sites)
Tangshan People's Hospital, Tangshan, Hebei 063000 China
Eligibility Criteria
Inclusion Criteria: * Diagnosis of unilateral breast cancer confirmed according to the Chinese Anti-Cancer Association Breast Cancer Diagnosis and Treatment Guidelines and Standards (2024 edition). * Underwent breast-conserving surgery and completed breast radiotherapy for at least 2 months prior to enrollment; skin toxicity ≤ Grade 1 according to the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria. * Age ≥ 18 years. * Ultrasound-diagnosed breast lymphedema in at least one quadrant of the affected breast exceeding the following thresholds: upper outer quadrant thickness ≥ 2.5 mm, upper inner quadrant ≥ 3.0 mm, lower outer quadrant ≥ 2.3 mm, lower inner quadrant ≥ 2.6 mm. * Presence of breast lymphedema symptoms (breast swelling, peau d'orange appearance, redness, positive Stemmer's sign) confirmed by clinical diagnosis. * Ability to understand and communicate effectively, capable of completing questionnaires. * Willing to provide written informed consent to participate in the study. Exclusion Criteria: * Cognitive impairment or communication dysfunction. * Severe psychological disorders or psychiatric illness. * Postoperative cancer recurrence or metastasis with serious complications. * Other causes of breast swelling unrelated to breast cancer. * Severe liver or kidney disease, cardiovascular disease, deep vein thrombosis, heart failure, lymphangitis, or current antibiotic treatment for cellulitis that would preclude participation. * Allergy to Kinesio Tape.
Conditions Breast Cancer, Chemotherapy
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is a public health issue with a high incidence among women worldwide, and its prevalence continues to increase each year. A breast cancer diagnosis brings significant physical, emotional, social, economic, and occupational changes. Chemotherapy, one of the most commonly used treatment modalities in cancer therapy, causes various physical and emotional symptoms while treating the disease. However, it is well known that these symptoms induced by chemotherapy can be prevented or alleviated through effective treatment and nursing interventions. Recently, virtual reality (VR) and mindfulness-based interventions have been reported as effective tools and methods for managing the physical and psychological symptoms experienced by cancer patients. The present study aims to evaluate the effect of a VR-integrated mindfulness-based intervention on anxiety, comfort, sleep, and fatigue levels among women newly diagnosed with breast cancer, both before and during chemotherapy treatment. The study is designed as a randomized controlled trial (RCT). The study population will consist of individuals diagnosed with breast cancer at the Oncology Outpatient Clinic of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital between May 2025 and December 2026. The study sample will include female breast cancer patients who are scheduled to receive adjuvant chemotherapy, meet the inclusion criteria, and volunteer to participate in the study. According to the power analysis (with a 30% additional error margin), a total of 50 participants will be included - 25 in the intervention group and 25 in the control group. The data will be collected using the following instruments: Patient Information Form, Beck Depression Inventory, Cancer Fatigue Scale, General Comfort Questionnaire-Short Form, State Anxiety Inventory, Jenkins Sleep Scale, and the Mindfulness-Based Self-Efficacy Scale. It is expected that, as a result of this study, compared to the control group, participants in the intervention group who receive the VR-Mindfulness intervention during breast cancer treatment will demonstrate reduced levels of fatigue and anxiety and improved comfort and sleep quality.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: VR-Based Mindfulness Intervention — The mindfulness intervention content was developed collaboratively by the research team and a mindfulness expert, based on a literature-informed design tailored to the study's aims and target population. Among the researchers, GCU has completed training in Mindfulness-Based Stress Reduction (MBSR), simulation-based practice, and has prior experience working with breast cancer patients. The mindfulness expert (EU), a licensed medical doctor, holds certifications in Mindfulness Teaching (Bangor University, UK), Professional Coaching (CTI), and the Mindfulness in Schools Project (UK). To align with the study objectives, mindfulness contents addressing anxiety, comfort, sleep, and fatigue were created by the team and the expert.

Primary Outcomes

  • Fatigue Assessed Using the Cancer Fatigue Scale (Assessed three times: after chemotherapy education and before Cycle 1; after the third virtual reality mindfulness session during Cycle 2; and after the sixth session, 2-3 weeks after Cycle 4. Cycles occur every 14 or 21 days.)
  • Comfort Assessed Using the General Comfort Questionnaire-Short Form (Assessed three times: after chemotherapy education and before Cycle 1; after the third virtual reality mindfulness session during Cycle 2; and after the sixth session, 2-3 weeks after Cycle 4. Cycles occur every 14 or 21 days.)
  • Sleep Quality Assessed Using the Jenkins Sleep Scale (Assessed three times: after chemotherapy education and before Cycle 1; after the third virtual reality mindfulness session during Cycle 2; and after the sixth session, 2-3 weeks after Cycle 4. Cycles occur every 14 or 21 days.)
  • Anxiety Assessed Using the State-Trait Anxiety Inventory-State Anxiety Subscale (Assessed three times: after chemotherapy education and before Cycle 1; after the third virtual reality mindfulness session during Cycle 2; and after the sixth session, 2-3 weeks after Cycle 4. Cycles occur every 14 or 21 days.)
  • Mindfulness-Based Self-Efficacy Assessed Using the Mindfulness-Based Self-Efficacy Scale-Revised (Assessed three times: after chemotherapy education and before Cycle 1; after the third virtual reality mindfulness session during Cycle 2; and after the sixth session, 2-3 weeks after Cycle 4. Cycles occur every 14 or 21 days.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2026-09-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hacettepe University
Contact Information
Study Contact:
GİZEM CANSIZ UÇAR, Registered Nurse
+905342396480
gizem.cansiz@atilim.edu.tr
GİZEM CANSIZ UÇAR, Registered Nurse
+905342396480
gizem.cansiz@atilim.edu.tr
Dr. Abdurrahman Yurtaslan Ankara Oncology Hospital, Ministry of Health, Republic of Turkey
Interventions
  • Behavioral: VR-Based Mindfulness Intervention — The mindfulness intervention content was developed collaboratively by the research team and a mindfulness expert, based on a literature-informed design tailored to the study's aims and target population. Among the researchers, GCU has completed training in Mindfulness-Based Stress Reduction (MBSR), simulation-based practice, and has prior experience working with breast cancer patients. The mindfulness expert (EU), a licensed medical doctor, holds certifications in Mindfulness Teaching (Bangor University, UK), Professional Coaching (CTI), and the Mindfulness in Schools Project (UK). To align with the study objectives, mindfulness contents addressing anxiety, comfort, sleep, and fatigue were created by the team and the expert.
Study Locations (1 sites)
Dr. Abdurrahman Yurtaslan Ankara Oncology Hospital, Ministry of Health, Republic of Turkey, Ankara, Ankara 06830 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: Newly diagnosed with breast cancer, Female and aged 18 years or older, Diagnosed with stage II or III breast cancer, Scheduled to receive chemotherapy for breast cancer for the first time in the adjuvant or neoadjuvant setting, using either the CA regimen \[C: cyclophosphamide; A: doxorubicin (Adriamycin)\] or the TC regimen \[T: docetaxel; C: cyclophosphamide\], with or without paclitaxel, trastuzumab, docetaxel, or carboplatin, Scheduled to receive chemotherapy but have not yet started treatment, Have a Beck Depression Inventory (BDI) score of ≤30, have no physician-diagnosed psychiatric disorder according to the DSM-5 diagnostic criteria, and are not receiving treatment for a psychiatric disorder (Appendix 8), Have completed at least primary school education, Voluntarily agree to participate in the study. Exclusion Criteria: Presence of metastasis, History of seizures, Presence of vertigo, Presence of motion sickness with a tendency toward nausea and vomiting, Communication difficulties, including hearing, visual, or speech impairments, Unwillingness to participate in the study. Withdrawal Criteria Participants will be withdrawn from the study if: They discontinue the treatment protocol at any stage, Their treatment protocol is changed, They no longer wish to continue participating in the study.
Conditions Metastatic Gastric Cancer, Metastatic Br...
Phase PHASE1
Enrollment 15
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a phase I, open-label, non-randomized, multicenter, dose-escalation trial designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of autologous p95HER2.CAR-TECH2Me T cells in patients with selected advanced HER2-positive (3+) cancers, including locally advanced, recurrent, or metastatic breast, gastric, endometrial, and other selected solid tumors. The study will also assess pharmacokinetics, pharmacodynamics, and immunogenicity of p95HER2.CAR-TECH2Me following intravenous administration. Treatment consists of non-myeloablative lymphodepletion chemotherapy with cyclophosphamide and fludarabine administered on Days -4 to -2, followed by a single infusion of p95HER2.CAR-TECH2Me cells on Day 0. The investigational product is a live cell suspension of autologous CAR-T lymphocytes derived from the patient's peripheral blood. Premedication will be administered before cell infusion according to protocol requirements. The primary objective of the study is to evaluate the safety and tolerability of p95HER2.CAR-TECH2Me and to identify the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). Primary endpoints include the nature and frequency of adverse events, serious adverse events, clinically relevant changes in laboratory parameters, electrocardiograms, vital signs, physical examination findings, and ECOG performance status, as well as the incidence and nature of dose-limiting toxicities. Adverse events will be graded according to NCI CTCAE v5.0, with cytokine release syndrome and neurotoxicity graded according to established consensus criteria. Secondary objectives include evaluation of preliminary anti-tumor activity and survival outcomes. Secondary endpoints include objective response rate, duration of response, progression-free survival according to RECIST v1.1 as assessed by the investigator, and overall survival. Approximately 15 patients are planned for enrollment over an estimated 36 to 48 months. The total study duration is expected to be approximately 60 months from the time the first subject signs the pre-screening informed consent form until the last subject completes the final study-related follow-up contact.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: p95HER2.CAR-TECH2Me — The treatment includes NMA-LD chemotherapy (cyclophosphamide 500 mg/m²/day + fludarabine 30mg/m2/day for three days) and p95HER2.CAR-TECH2Me cell infusion (1 day). The p95HER2.CAR-TECH2Me product is a cellular investigational product comprising a live cell suspension of autologous CAR-T lymphocytes derived from the patient's peripheral blood.

Primary Outcomes

  • Number of participants with adverse events and serious adverse events graded according to CTCAE v5.0 (Up to 3 months after the infusion)
  • Number of participants with clinically significant abnormalities in clinical safety laboratory tests (Up to 3 months after the infusion)
  • Number of participants with clinically significant abnormalities in 12-lead electrocardiogram findings (Up to 3 months after the infusion)
  • Number of participants with clinically significant abnormalities in vital sign measurements (Up to 3 months after the infusion)
  • Number of participants with clinically significant abnormalities in physical examination findings (Up to 3 months after the infusion)
  • Change from baseline in Eastern Cooperative Oncology Group (ECOG)performance status score (Up to 3 months after the infusion)
  • Number of participants with dose-limiting toxicities during the dose-limiting toxicity assessment period (28 days since the administration.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-04-29
Completion: 2041-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vall d'Hebron Institute of Oncology
Collaborators: Banc de Sang i Teixits, Consorci Mar Parc de Salut de Barcelona
Contact Information
Study Contact:
Irene Braña, Dr
+932746085
ibrana@vhio.net
Joan Albanell, Dr
+932483137
jalbanell@psmar.cat
Hospital Del Mar
Irene Braña, Dr
+932746085
ibrana@vhio.net
Hospital Universitari Vall D Hebron
Interventions
  • Biological: p95HER2.CAR-TECH2Me — The treatment includes NMA-LD chemotherapy (cyclophosphamide 500 mg/m²/day + fludarabine 30mg/m2/day for three days) and p95HER2.CAR-TECH2Me cell infusion (1 day). The p95HER2.CAR-TECH2Me product is a cellular investigational product comprising a live cell suspension of autologous CAR-T lymphocytes derived from the patient's peripheral blood.
Study Locations (2 sites)
Hospital Del Mar, Barcelona, Catalonia 08003 Spain
Hospital Universitari Vall D Hebron, Barcelona, Catalonia 08035 Spain
Eligibility Criteria
Inclusion Criteria: 1. Patients must understand and voluntarily sign an informed consent document before any study-related assessments/procedures being conducted. 2. Age ≥ 18 and years at the time of signing the ICF 3. Patients must be able and willing to comply with the study visit schedule and protocol requirements. 4. Patients must have a clinical performance of Eastern Cooperative Oncology Group 0 or 1. 5. Life expectancy ≥12 weeks. 6. Patients must have histologically or cytologically proven unresectable or metastatic tumors. The disease must be refractory to standard therapy or in the first line if they are unable to receive standard therapy or no standard therapy exists for a particular disease. a) Select tumor types: breast, gastric, and endometrial tumors. Other selected solid tumors may be included per investigator discretion if the potential benefit is considered based on the literature updates in HER2/p95HER2 expression. 7. Positivity for HER2 expression according to international society guidelines (score in a ISO-certified clinical or equivalent laboratory). To meet study entry eligibility, tumors are required to have at least an intensity score 3+ for HER2 staining following the manufacturer's recommendations 8. Measurable disease by the RECIST v. 1.1 criteria (See Section 7.2 for details). Note: Lesions previously irradiated should not be selected as target lesions unless there has been demonstrated progression in those lesions; 9. Patients are considered medically fit enough to undergo all study procedures and interventions and adequate hematological, renal, and hepatic functions defined by: 1. Hemoglobin ≥ 9.0 g/dL. 2. An absolute neutrophil count ≥ 1x10E9/L without the support of filgrastim 3. Platelets ≥ 100 x10E9/L. 4. PT and APTT ≤ 1.5x ULN (unless receiving therapeutic anticoagulation). Note: Subjects receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable dose. 5. AST or ALT ≤ 3 x ULN. Patients with liver metastases must have AST and ALT ≤ 5.0 x ULN. 6. Total bilirubin \< 2 mg/dL. Patients with Gilbert's Syndrome must have a total bilirubin ≤ 3.0 mg/dL. 7. Serum creatinine \< 1.5 mg/dL or measured creatinine clearance ≥ 50 ml/min calculated using the Cockcroft-Gault glomerular filtration rate estimation: (140 - age) × (weight in kg) × (0.85 if female)/72 × (serum creatinine in mg/dL). 10. Patients must be seronegative for HIV antibody. 11. Patients must be seronegative for active hepatitis B (defined as having a negative hepatitis B surface antigen \[HBsAg\] test), and seronegative for hepatitis C antibody. Patients with a history of hepatitis B virus (HBV) infection and having a negative HBsAg test and a positive antibody to hepatitis B surface antigen (HBsAg) are eligible. Patients with the hepatitis C antibody test positive are eligible only if tested for the presence of antigen by RT-PCR and be HCV RNA negative. 12. Patients must have blood tests results negative for active tuberculosis, syphilis, herpes simplex virus, cytomegalovirus, HTLV or Epstein-Barr virus infection. 13. Patients with documented LVEF of ≥ 50%. 14. Patients with documented FEV1, FVC, and DLCO ≥ 50% tested by a pulmonary function test. 15. Patients who are of childbearing potential (postmenarcheal who has not reached a postmenopausal state and has not undergone surgical sterilization) or have partners of childbearing potential must agree to use a highly effective method of contraception during the study and for at least 12 months after the infusion of the p95HER2.CAR-TECH2Me product . 16. Female participants: a female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: 1. Women of non-childbearing potential (WONCBP). 2. Women of childbearing potential (WOCBP), who: i) Agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \<1% per year from screening until 12 months after the infusion of the p95HER2.CAR-TECH2Me product. Examples of contraceptive methods with a failure rate of \<1% per year include bilateral tubal occlusion, male sterilization, and copper intrauterine devices. ii) Have a negative pregnancy test (blood) within one week before the first study treatment administration (applicable to premenopausal women and women 2 years after the start of menopause (menopause is defined as amenorrhea for \< 2 years). 17. Male Participants: during the treatment period and for at least 6 months after the last dose of study treatment, agreement to: 1. Remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures such as a condom or a contraceptive method that result in a failure rate of \<1% per year, with partners who are WOCBP. 2. Refrain from donating sperm during the study. 3. Inform if his partner gets pregnant during this time. 18. Adequate expanding p95HER2.CAR-TECH2Me cells as defined by the T cell production manual before preparative lymphodepleting chemotherapy infusion (available autologous transduced T lymphocytes with 15% or more expression of p95HER2.CAR-TECH2Me as determined by flow-cytometry and killing of p95HER2-positive targets 20 % or greater in cytotoxicity assay.) 19. Any toxicity related to prior systemic therapy must have recovered to grade 1 or less according to NCI-CTCAE v5.0 at least 4 weeks before treatment enrollment, except for alopecia, vitiligo, or endocrinopathy managed with replacement therapy, and Grade 2 peripheral neuropathy. Note: Other Grade 2 AEs that are deemed clinically insignificant by treating physician and in consultation with Medical Monitor are permitted. 20. Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less. Exclusion Criteria: 1. Patients with symptomatic and/or untreated brain metastases. Note: Patients with definitively-treated brain metastases will be considered for enrollment after discussion with Medical Monitor if prior to the start of NMA-LD the patient is asymptomatic, clinically stable for ≥3 months, there are no new brain lesions via magnetic resonance imaging (MRI) post-treatment, and the patient does not require corticosteroid treatment. 2. Patients with leptomeningeal carcinomatosis. 3. Patients with an active concurrent or history within the past 3 years of invasive malignancy, except for non-melanoma skin cancer, cervical and bladder carcinoma in situ, good prognosis ductal carcinoma in situ of the breast, or prostate carcinoma that is in remission under androgen deprivation therapy for \> 2 years. Other exceptions may apply and require discussion between the Investigator and the Medical Monitor. 4. Patients with an active systemic infection requiring anti-infective treatment within 14 days before preparative lymphodepleting therapy. 5. Patients with active hepatitis B or hepatitis C. 6. Patients with active autoimmune disease requiring immunosuppressive treatments. 7. Patients with a history of organ or bone marrow transplantation. 8. Patients with any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease and AIDS). 9. Patients requiring regular treatment with steroids. Note: use of inhaled, topical steroids and use of systemic physiologic corticosteroid replacement therapy are permitted. 10. Patients with current or history within the last 6 months, as determined by the Investigator, of clinically significant, progressive, and/or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, gastroenterological or neurological disease. 11. Patients with a history of coronary revascularization or ischemic symptoms. 12. History of idiopathic pulmonary fibrosis or evidence of active pneumonitis (any origin) 13. Patients with allergies to any of the compounds included in
Conditions Major Depressive Episode (MDE), Major De...
Phase PHASE2
Enrollment 360
Locations 27 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL. The main questions it aims to answer are: Does TNX-102 SL improve depression symptoms according to a depression symptom rating scale? What medical problems do participants have when taking TNX-102 SL? Researchers will compare TNX-102 SL to a placebo (a look-alike substance that contains no drug) to see if TNX-102 SL works to treat major depressive disorder. Participants will: Take TNX-102 SL or a placebo every night at bedtime for 6 weeks Visit the clinic once every 2 weeks for checkups and tests

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: TNX-102 SL — Participants will take 5.6 mg of TNX-102 SL ( 2 x 2.8 mg TNX-102 SL tablets) daily at bedtime.
  • Drug: Placebo sublingual tablet — Participants will take placebo ( 2 x placebo sublingual tablets) daily at bedtime.

Primary Outcomes

  • Change from Baseline (Visit 2) in the MADRS total score at Week 6. (From Day 1 to Week 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-06-25
Completion: 2028-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 360 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tonix Pharmaceuticals, Inc.
Contact Information
Study Contact:
Timothy Roush
(862) 799-8599
timothy.roush@tonixpharma.com
Interventions
  • Drug: TNX-102 SL — Participants will take 5.6 mg of TNX-102 SL ( 2 x 2.8 mg TNX-102 SL tablets) daily at bedtime.
  • Drug: Placebo sublingual tablet — Participants will take placebo ( 2 x placebo sublingual tablets) daily at bedtime.
Study Locations (27 sites)
IMA Clinical Research- Phoenix, Phoenix, Arizona 85012 United States
Buena Park Research Center, Buena Park, California 90620 United States
Inland Psychiatric Medical Group, Inc. - Chino, Chino, California 91710 United States
Synergy Research - San Diego, Lemon Grove, California 91945 United States
Nrc Research Institute, Orange, California 92868 United States
Artemis Institute For Clinical Research - San Diego, San Diego, California 92123 United States
Sunwise Clinical Research, Llc, Walnut Creek, California 94596 United States
Clinical Neuroscience Solutions Inc. - Jacksonville, Jacksonville, Florida 32256 United States
K2 Medical Research - Maitland, Maitland, Florida 32751 United States
Central Miami Medical Institute Llc., Miami, Florida 33125 United States
Eligibility Criteria
Inclusion Criteria: * Primary DSM-5 diagnosis of current MDD. * The duration of the current MDE must be between 6 weeks and 18 months. * Without psychotic or catatonic features. * Capable of reading and understanding English and able to provide written informed consent to participate. Exclusion Criteria: * Diagnosis of DSM-5-defined lifetime bipolar disorder (I, II, or unspecified), schizophrenia, schizoaffective disorder, MDD with psychotic features, other psychotic disorder, or antisocial personality disorder; current (past month) obsessive-compulsive disorder; current (past month) posttraumatic stress disorder; current (past 3 months) anorexia nervosa, * Diagnosis of borderline personality disorder that is known, suspected * Participants with comorbid generalized anxiety disorder (GAD), social anxiety disorder (SAD), or panic disorder are excluded only if the GAD, SAD, or panic disorder is considered the primary psychiatric diagnosis, rather than MDD. * Participants with treatment refractory MDD, ie, previously having failed in their lifetime ≥2 treatments (due to inadequate efficacy) with at least 2 different classes of antidepressants of adequate dose, duration, and treatment adherence. * History of substance use disorder and/or alcohol use disorder during the preceding 12 months * Use of antidepressants (including ketamine/esketamine, St. John's Wort, S-adenosyl methionine, and/or trazodone used as an antidepressant) within 4 weeks of Baseline (Visit 2), except for fluoxetine, which must not be within 6 weeks of Baseline (Visit 2)
Conditions Breast Cancer, Breast Cancer Risk
Phase NA
Enrollment 291
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This prospective study evaluates whether a more detailed clinical and genetic assessment can improve the classification of individual breast cancer risk among women previously identified as having moderately increased or high breast cancer risk in the Slovenian DORA breast cancer screening programme. Women who agree to participate complete questionnaires and attend an individual genetic counseling appointment at the Institute of Oncology Ljubljana. Personal breast cancer risk factors are reviewed with the assistance of a specialist, and reported family cancer history is verified using data from the Slovenian Cancer Registry. Breast cancer risk is reassessed using the S-IBIS and CanRisk models. Genetic testing is offered to participants who meet the applicable clinical criteria. The study will evaluate changes in breast cancer risk classification, compare risk estimates obtained using the S-IBIS and CanRisk models, and provide participants with individualized recommendations for breast cancer screening and follow-up according to their reassessed risk.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Other: Comprehensive Clinical and Genetic Breast Cancer Risk Assessment — Participants receive an individual clinical and genetic breast cancer risk assessment. Personal risk factors are reviewed with the assistance of a specialist, and family cancer history is verified using the Slovenian Cancer Registry. Breast cancer risk is calculated using the S-IBIS and CanRisk models. Genetic counseling is provided, and genetic testing is performed when the participant meets the applicable clinical criteria. Recommendations for screening and follow-up are adapted to the reassessed level of breast cancer risk.

Primary Outcomes

  • Proportion of Participants Reclassified to Population-Level Breast Cancer Risk (Through study completion, up to 34 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-10
Completion: 2027-12-31
Eligibility
Age: 53 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 291 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institute of Oncology Ljubljana
Contact Information
Study Contact:
Clinical Cancer Genetics Clinic
+386 1 587 9649
genetika@onko-i.si
Katja Jarm, MD, PhD
+38615879573
kjarm@onko-i.si
Institute of Oncology Ljubljana
Interventions
  • Other: Comprehensive Clinical and Genetic Breast Cancer Risk Assessment — Participants receive an individual clinical and genetic breast cancer risk assessment. Personal risk factors are reviewed with the assistance of a specialist, and family cancer history is verified using the Slovenian Cancer Registry. Breast cancer risk is calculated using the S-IBIS and CanRisk models. Genetic counseling is provided, and genetic testing is performed when the participant meets the applicable clinical criteria. Recommendations for screening and follow-up are adapted to the reassessed level of breast cancer risk.
Study Locations (1 sites)
Institute of Oncology Ljubljana, Ljubljana, 1000 Slovenia
Eligibility Criteria
Inclusion Criteria: \- Women who participated in the previous DORA study and were classified by the S-IBIS model as having moderately increased or high breast cancer risk. Exclusion Criteria: * Diagnosis of breast cancer.
Conditions Depression, Anxiety, Heart Injuries
Phase Not Applicable
Enrollment 200
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the potential usefulness of 18F-AIPF-1026 positron emission tomography/ computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various MAO-A-related disease patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Diagnostic Test: 18F-AIPFA-1026 — Each subject receive a single intravenous injection of 18F-AIPF-1026, and undergo PET/ CT or MRI imaging within the specificed time.

Primary Outcomes

  • Standardized uptake value (SUV) (30 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-06-25
Completion: 2029-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tianjin Medical University
Collaborators: Tianjin Medical University General Hospital
Contact Information
Study Contact:
Ying Wang, MD
+8618702292537
macrossplusvoices@163.com
Qiang Xie, PhD
+8613721108043
ahxq1980@163.com
The First Affiliated Hospital of University of Science and Technology of China
Guangjie Yang, MD
+8617853297979
ygj_2815@qdu.edu.cn
The Affiliated Hospital of Qingdao University
Interventions
  • Diagnostic Test: Diagnostic Test: 18F-AIPFA-1026 — Each subject receive a single intravenous injection of 18F-AIPF-1026, and undergo PET/ CT or MRI imaging within the specificed time.
Study Locations (3 sites)
The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui 230000 China
The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000 China
Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality 300052 China
Eligibility Criteria
Inclusion Criteria: \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated depression (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled MAO-A PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Conditions Hypertension (HTN), Preeclampsia, Hypert...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Strategies targeted to optimize hypertension (HTN) control for midlife women after hypertensive disorders of pregnancy (HDP) have not been studied, despite evidence of a critical need. This proposal targets the 10-20 years postpartum as a key time when women have subclinical cardiovascular (CV) sequelae of uncontrolled HTN and are primed for CV prevention interventions. Before proceeding with large-scale intervention trials of a home blood pressure monitoring (HBPM) and coaching intervention following HDP, further pilot testing is necessary. The overarching hypothesis of this proposal is that a new monitoring and treatment paradigm utilizing HBPM combined with a virtual coaching intervention would be better than standard of care for mid-life women with prior HDP who develop HTN. Women will be assigned in an unblinded manner to the intervention or standard of care control group.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Coaching application — A digital application for providing education and support for home-based blood pressure monitoring.
  • Behavioral: Home-based blood pressure monitoring — Device for measuring blood pressure at home with blue tooth connectivity for automated collection.
  • Other: WebMD — Smartphone-based application for health education and/or monitoring.

Primary Outcomes

  • Change in systolic blood pressure from baseline to 3 months (Baseline, 3 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-22
Completion: 2027-10
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: McKamish Family Foundation
Principal Investigators:
  • Malamo Countouris, MD, MS (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Amy Travis
4126413295
travisam@upmc.edu
Samantha Bryan
412-641-1363
myslinskisg@mwri.magee.edu
Amy Travis
4126413295
travisam@upmc.edu
UPMC Magee Womens Hospital
Interventions
  • Behavioral: Coaching application — A digital application for providing education and support for home-based blood pressure monitoring.
  • Behavioral: Home-based blood pressure monitoring — Device for measuring blood pressure at home with blue tooth connectivity for automated collection.
  • Other: WebMD — Smartphone-based application for health education and/or monitoring.
Study Locations (1 sites)
UPMC Magee Womens Hospital, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria: * Women who had a history of HDP (either gestational HTN or preeclampsia) diagnosed by ACOG guidelines at the time of delivery at Magee-Womens Hospital between 2008 and 2015, thus 10 to 20 years from their index pregnancy complicated by HDP. * Evidence of current stage 2 HTN (BP ≥ 140/90 mmHg with or without treatment with antihypertensive medication). Exclusion Criteria: * Known clinical CVD (prior myocardial infarction, stroke, heart failure, or peripheral arterial disease). * Males will also be excluded from this study as it focuses on pregnancy related conditions. * Children will be excluded as the study is only recruiting people who are 10-20 years postpartum.
Conditions Hypertension, Poor Sleep Quality, Insomn...
Phase NA
Enrollment 234
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This prospective, parallel-group randomised controlled trial evaluates whether cognitive-behavioural therapy for insomnia (CBT-I) improves arterial function and psychological and cognitive outcomes in hypertensive patients with poor sleep quality. Adults aged 18-70 with controlled hypertension and poor baseline sleep quality (sleep efficiency \<=85%) are randomised 1:1 to CBT-I (four weekly 60-minute sessions) or passive sleep education. The primary outcomes are change from baseline in pulse wave velocity and central arterial pressure at 12 months. Secondary outcomes include blood pressure, depressive symptoms, perceived stress, cognitive complaints, and sleep quality, assessed at baseline, 1, 6, and 12 months.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Behavioral: Cognitive-Behavioural Therapy for Insomnia (CBT-I) — Cognitive-behavioural therapy for insomnia delivered in four weekly 60-minute sessions, incorporating sleep hygiene, stimulus control, and relaxation techniques. Based on baseline polysomnography, the protocol is adapted for participants without obstructive sleep apnea, with mild obstructive sleep apnea, or with comorbid insomnia and mild sleep apnea (COMISA).
  • Behavioral: Passive sleep education — Passive sleep education consisting of informational leaflets plus non-interactive follow-up calls. Participants in this control condition are offered access to CBT-I after study completion.

Primary Outcomes

  • Change from baseline in pulse wave velocity (PWV) (Baseline, 1 month, 6 months, and 12 months)
  • Change from baseline in central arterial pressure (CAP) (Baseline, 1 month, 6 months, and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-18
Completion: 2030-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 234 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Unidade Local de Saúde do Alto Ave, EPE
Principal Investigators:
  • Sofia Gomes, MD (PRINCIPAL_INVESTIGATOR) - Unidade Local de Saúde do Alto Ave
  • Pedro Cunha, PhD (STUDY_DIRECTOR) - Unidade Local de Saúde do Alto Ave
Contact Information
Study Contact:
Sofia Gomes, MD
+ 351 253540330
3603@ulsaave.min-saude.pt
Sofia Gomes, MD
+351 253 540 330
3603@ulsaave.min-saude.pt
Unidade Local de Saúde do Alto Ave - Hospital Senhora da Oliveira
Pedro Cunha, PhD
+351 253 540 330
pedrocunha@ulsaave.min-saude.pt
Unidade Local de Saúde do Alto Ave - Hospital Senhora da Oliveira
Interventions
  • Behavioral: Behavioral: Cognitive-Behavioural Therapy for Insomnia (CBT-I) — Cognitive-behavioural therapy for insomnia delivered in four weekly 60-minute sessions, incorporating sleep hygiene, stimulus control, and relaxation techniques. Based on baseline polysomnography, the protocol is adapted for participants without obstructive sleep apnea, with mild obstructive sleep apnea, or with comorbid insomnia and mild sleep apnea (COMISA).
  • Behavioral: Passive sleep education — Passive sleep education consisting of informational leaflets plus non-interactive follow-up calls. Participants in this control condition are offered access to CBT-I after study completion.
Study Locations (1 sites)
Unidade Local de Saúde do Alto Ave - Hospital Senhora da Oliveira, Guimarães, Braga District 4835-044 Portugal
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 70 years * Controlled hypertension * Poor baseline sleep quality (sleep efficiency \<=85% assessed via actigraphy or type II polysomnography) * Capable of providing informed consent * Participants with mild obstructive sleep apnea (apnea-hypopnea index 5-14.9/h on type II polysomnography) who do not meet criteria for CPAP/PAP therapy are eligible Exclusion Criteria: * Severe cardiovascular disease (e.g., acute myocardial infarction or stroke) * Severe neurological diseases * Moderate-to-severe obstructive sleep apnea (AHI \>=15/h) or any obstructive sleep apnea with an indication for CPAP/PAP therapy * Central disorders of hypersomnolence * Intellectual disability * Pregnancy